Regulation of Memory B Cell Responses to Polysaccharide Antigens
记忆 B 细胞对多糖抗原反应的调节
基本信息
- 批准号:9465418
- 负责人:
- 金额:$ 38.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-05-01 至 2020-04-30
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdultAgonistAntibodiesAntibody FormationAntibody ResponseAntibody titer measurementAntigensB-LymphocytesBacteriaBindingC Type Lectin ReceptorsCD22 geneCD28 geneCD80 geneCTLA4 geneCarbohydratesCell divisionCellsCessation of lifeChildCommunicable DiseasesComplementComplement ReceptorComplexConjugate VaccinesCytotoxic T-Lymphocyte-Associated Protein 4DataDevelopmentDiseaseEncapsulatedFunctional disorderFutureGenerationsGoalsImmune systemImmunizationImmunoglobulin GImmunoglobulin MImmunoglobulin-Secreting CellsImmunoglobulinsImmunosuppressionImpairmentIndividualInfectionKnowledgeLeadLectinLectin ReceptorsLigandsLinkLipid AMediatingMemoryMemory B-LymphocyteModificationPDCD1LG1 genePathway interactionsPattern recognition receptorPlayPneumococcal InfectionsPneumococcal vaccinePneumovaxPolysaccharidesPolyvalent pneumococcal vaccineProteinsPublic HealthRegulationRegulatory PathwayResearchResearch PersonnelRoleSLEB2 geneSecondary ImmunizationSecondary toSerotypingSialic AcidsSignal TransductionStreptococcusStreptococcus pneumoniaeSuppressor-Effector T-LymphocytesT-LymphocyteTLR4 geneTestingTimeToll-like receptorsTrehaloseUrsidae FamilyVaccinationVaccinesWorkbasecancer therapycostdesignimprovedpreventpublic health relevancereceptorresponsesialic acid binding Ig-like lectinsialic acid receptorsialylationsynergismtraffickingvaccine efficacy
项目摘要
DESCRIPTION (provided by applicant): Streptococcus neumoniae kills more people in the U.S. than all other vaccine-preventable diseases combined and causes over 1.6 million deaths/year worldwide. The native pneumococcal vaccine currently used in adults consists of capsular polysaccharides (PPS) derived from 23 different serotypes and therefore provides broad coverage against invasive disease. Nonetheless, protection eventually wanes as antibody titers diminish, typically by 10 years post-vaccination. Unfortunately, PPS boosting does not induce recall responses. This is typical of most polysaccharide (Ps) antigens. This is a significant concern given the potential for diminished protection against pneumococcal infections. PPS-protein conjugate vaccines do not effectively boost or yield superior titers to native PPS in adults, in contrast to what is observed in young children. This, along with the high cost and limited serotype coverage of conjugate vaccines, suggests that alternative strategies are needed to enhance PPS vaccine efficacy. To improve native Ps vaccines, it is imperative to develop a mechanistic understanding of the factors preventing Ps-specific antibody recall responses. Our data supports that memory B cells are generated in response to Ps antigens but that they are largely unresponsive when antigen is re- encountered following infection or revaccination. Antigen-specific IgG may play a part by suppressing Ps- specific IgM recall responses. However, our data supports additional mechanisms of suppression contribute to not only to impaired IgM, but IgG, boosting to Ps antigens. In this proposal, we will test the hypothesis that active mechanisms of receptor-mediated immune suppression limit Ps-specific memory B cell generation and functional responsiveness to secondary antigen encounter. In addition, we will test the hypothesis that strong "danger" signals supplied through toll-like (TLR)
and C-type lectin receptors (CLR) can overcome this suppression. In Aim 1, we will examine the B cell-intrinsic and -extrinsic roles for B7:CD28 superfamily inhibitory receptors and ligands in suppressing Ps-specific memory B cell formation and effector function. In Aim 2, we will investigate mechanisms by which Ps-specific antibody suppresses boosting. In Aim 3, we will examine the extent to which TLR4/RP105 and Mincle agonists synergize to promote Ps-specific memory B cell generation and functional responsiveness during boosting. We will examine the mechanisms by which this is achieved, including the extent to which these agonists overcome the inhibitory pathways examined in Aims 1 and 2. Completion of these studies is expected to provide critical knowledge regarding the mechanisms responsible for suppressed secondary antibody responses to native Ps as well as the feasibility of using TLR and CLR-based adjuvant combinations to overcome this barrier to effective vaccination. Our results are expected to have a significant impact on the use of prime-boost strategies employing native Ps, as well as the future design of more affordable and efficacious Ps-based vaccines with the highest possible serotype coverage.
描述(由申请人提供):在美国,肺炎链球菌导致的死亡人数超过所有其他疫苗可预防疾病的总和,每年导致全球超过160万人死亡。目前用于成人的本土肺炎球菌疫苗由来自23个不同血清型的荚膜多糖(PPS)组成,因此提供了广泛的覆盖范围,可预防侵袭性疾病。尽管如此,随着抗体效价的下降,保护力最终会减弱,通常是在接种疫苗后10年。不幸的是,PPS增强并不能引发回忆反应。这是大多数多糖(Ps)抗原的典型特征。考虑到对肺炎球菌感染的保护作用可能减弱,这是一个重大关切。与在幼儿中观察到的情况相反,PPS-蛋白质结合疫苗在成人中并不能有效地提高或产生比天然PPS更高的滴度。这一点,再加上结合疫苗的高成本和有限的血清型覆盖范围,表明需要替代策略来提高PPS疫苗的效力。为了改进本土的Ps疫苗,必须从机制上理解阻止Ps特异性抗体召回反应的因素。我们的数据支持记忆B细胞是对Ps抗原产生的,但当感染或重新接种后再次遇到抗原时,它们基本上没有反应。抗原特异性的免疫球蛋白可能通过抑制Ps特异性的IgM回忆反应而发挥作用。然而,我们的数据支持额外的抑制机制,不仅有助于受损的IgM,而且有助于促进Ps抗原的免疫球蛋白G。在这个提议中,我们将检验这样一个假设,即受体介导的免疫抑制的活跃机制限制了Ps特异性记忆B细胞的生成和对次级抗原相遇的功能反应。此外,我们将检验这样一种假设,即通过类长途(TLR)提供的强“危险”信号
而C型凝集素受体(CLR)可以克服这种抑制。在目标1中,我们将研究B7:CD28超家族抑制性受体和配体在抑制Ps特异性记忆B细胞形成和效应功能中的内在和外在作用。在目标2中,我们将研究Ps特异性抗体抑制启动子的机制。在目标3中,我们将研究TLR4/RP105和Mincle激动剂在多大程度上协同促进Ps特异性记忆B细胞的生成和增强过程中的功能反应。我们将研究实现这一目标的机制,包括这些激动剂克服AIMS 1和AIMS 2中检查的抑制途径的程度。这些研究的完成有望提供关于对天然P蛋白的二次抗体反应被抑制的机制以及使用TLR和CLR佐剂组合来克服有效疫苗接种这一障碍的可行性的关键知识。我们的结果预计将对使用本地Ps的Prime-Boost策略的使用产生重大影响,以及未来设计更负担得起、更有效的具有最高血清型覆盖率的Ps疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karen M Haas其他文献
Karen M Haas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karen M Haas', 18)}}的其他基金
Role of B cells in controlling Klebsiella pneumoniae associated disease states
B 细胞在控制肺炎克雷伯菌相关疾病状态中的作用
- 批准号:
10731411 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
Leveraging B cell specificities for tumor glycans to elicit potent anti-tumor immunity
利用 B 细胞对肿瘤聚糖的特异性来引发有效的抗肿瘤免疫
- 批准号:
10502322 - 财政年份:2022
- 资助金额:
$ 38.44万 - 项目类别:
THE IMPACT OF ADVANCED AGE AND SEX ON HUMORAL IMMUNITY TO STREPTOCOCCUS PNEUMONIAE
高龄和性别对肺炎链球菌体液免疫的影响
- 批准号:
10532071 - 财政年份:2022
- 资助金额:
$ 38.44万 - 项目类别:
Leveraging B cell specificities for tumor glycans to elicit potent anti-tumor immunity
利用 B 细胞对肿瘤聚糖的特异性来引发有效的抗肿瘤免疫
- 批准号:
10662537 - 财政年份:2022
- 资助金额:
$ 38.44万 - 项目类别:
THE IMPACT OF ADVANCED AGE AND SEX ON HUMORAL IMMUNITY TO STREPTOCOCCUS PNEUMONIAE
高龄和性别对肺炎链球菌体液免疫的影响
- 批准号:
10693951 - 财政年份:2022
- 资助金额:
$ 38.44万 - 项目类别:
Viral Modulation of Polysaccharide Antibody Responses and Vaccine Efficacy
多糖抗体反应和疫苗功效的病毒调节
- 批准号:
9018144 - 财政年份:2016
- 资助金额:
$ 38.44万 - 项目类别:
Regulation of Memory B Cell Responses to Polysaccharide Antigens
记忆 B 细胞对多糖抗原反应的调节
- 批准号:
8944119 - 财政年份:2015
- 资助金额:
$ 38.44万 - 项目类别:
Regulation of Memory B Cell Responses to Polysaccharide Antigens
记忆 B 细胞对多糖抗原反应的调节
- 批准号:
9266278 - 财政年份:2015
- 资助金额:
$ 38.44万 - 项目类别:
Regulation of Memory B Cell Responses to Polysaccharide Antigens
记忆 B 细胞对多糖抗原反应的调节
- 批准号:
9056974 - 财政年份:2015
- 资助金额:
$ 38.44万 - 项目类别:
REGULATION OF MEMORY B CELL RESPONSES TO POLYSACCHARIDE ANTIGENS
记忆 B 细胞对多糖抗原反应的调节
- 批准号:
8820783 - 财政年份:2014
- 资助金额:
$ 38.44万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 38.44万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 38.44万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 38.44万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 38.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 38.44万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 38.44万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 38.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)